BETTER BP CONTROL AND ACTIVE CARDIOVASCULAR
RISK REDUCTION WITH ADALAT
®
XL
2
ADALAT
®
XL
•
significantly lowers blood pressure while reducing cardiovascular risk
3
•
can be safely used for the long-term treatment of patients with coronary disease
and angina pectoris
4
•
is effective and safe in a broad spectrum of patients
3
ADALAT
®
XL 20
•
provides a low nifedipine dose for initial therapy or
combination therapy and allows for greater flexibility
in dosing
1
References: 1.
ADALAT
®
XL package insert.
2.
Constance C. Which CCB is the better choice?
Clinicians Corner
2003;Volume 1.
3.
Heagerty AM. Nifedipine gastrointestinal therapeutic system – Hypertension
management to improve cardiovascular outcomes.
Int J Clin Pract
2005;59:1112-1119.
4.
Poole-Wilson PA, Lubsen J, Kirwan BA,
et al
. Effect of long-acting nifedipine on mortality and cardiovascular morbidity
in patients with stable angina requiring treatment (ACTION trial): randomized, controlled trial.
Lancet
August 31, 2004.
S3 ADALAT
®
XL 20 Tablets. Each tablet contains 20 mg nifedipine. Reg. No.: A39/7.1/0634. S3 ADALAT
®
XL 30 Tablets. Each tablet contains 30 mg nifedipine. Reg. No.: Y/7.1/314. S3 ADALAT
®
XL
60 Tablets. Each tablet contains 60 mg nifedipine. Reg. No.: Y/7.1/315. For full prescribing information refer to the package insert approved by the medicines regulatory authority. ZA.GM.ADAL.11-2009.0012
Long-term commitment to
Life
Bayer (Pty) Ltd, Reg. No.: 1968/011192/07, t/a Bayer Schering Pharma. 27 Wrench Road, Isando, 1609. Tel: (011) 921-5911.
122274
